Table 1.
Baseline characteristics of participants included in the study
| Healthy Individudals (n = 41) | Primary Immuno-deficiencies (n = 16) | People Living With HIV (n = 48) | Solid Organ Transplantation (n = 34*) | |
|---|---|---|---|---|
| Sex, n (%) | ||||
| Men | 19 (46%) | 8 (50%) | 26 (54%) | 18 (53%) |
| Women | 22 (54%) | 8 (50%) | 22 46%) | 16 (47%) |
| Age < 65 years, n (%) | 28 (68%) | 13 (81%) | 37 (77%) | 24 (71%) |
| Ongoing immune-suppression, n (%) | ||||
| Corticosteroids | 0 | 0 | 0 | 32 (94%) |
| Other immune-suppressive agents | 0 | 1 (6%) | 0 | 34 (100%) |
| Subgroups (n) |
1. 18–39 years (n = 16) 2. 40–59 years (n = 12) 3. > 60 years (n = 13) |
1. CVID (n = 3) 2. Low number or defect T-cell function (n = 8) 3. Monogenic diseases (n = 2) 4. Other with expected normal response (n = 3) |
1. Latest CD4 T cell count ≤ 300 cells/μl (n = 16) 2. Latest CD4 T cell count > 300 cells/μl (n = 32) |
Time after transplantation: 1. ≤ 6 mo (n = 19) with/without MMF 2. > 6 mo with MMF (n = 6) 3. > 6 mo without MMF (n = 9) |
n number, HIV human immunodeficiency virus, CVID common variable immunodeficiency, IgA immunoglobulin A, CD cluster of differentiation, MMF mycophenolate mofetil.
*The different transplants in the SOT group (n = 34) were liver (n = 19), kidney (n = 14) and kidney and pancreas (n = 1)